A strong second quarter pushed Novartis’s stock up 5% this morning, but Kymriah continues to look weak, and the jury is still out on Zolgensma.
Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.
Turning Point is heading into a highly competitive lung cancer niche with its lead project, which still has much to prove.
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.
By taking out Abide Therapeutics, Lundbeck has bought one of very few clinical-stage Tourette’s syndrome candidates.
Abbvie will need more than Skyrizi and upadacitinib to fill a Humira-shaped hole, and there are a few early-stage candidates it reckons could fit the bill.
The upcoming American Academy of Neurology meeting could provide clues on how the market will shake out.